FOLFIRINOX for locally advanced pancreatic cancer: Results and prognostic factors of subset analysis from a nation-wide multicenter observational study in Japan-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

FOLFIRINOX for locally advanced pancreatic cancer: Results and prognostic factors of subset analysis from a nation-wide multicenter observational study in Japan

Published:2019-03 Issue:2 Volume:19 Page:296-301
ISSN:1424-3903
Container-title:Pancreatology
language:en
Short-container-title:Pancreatology

Author:

Matsumoto Ippei,Kamei Keiko,Omae Katsuhiro,Suzuki Shuhei,Matsuoka Hidehiko,Mizuno Nobumasa,Ozaka Masato,Ueno Hideki,Kobayashi Satoshi^ORCID,Uesugi Kazuhiro,Kobayashi Marina,Todaka Akiko,Fukutomi Akira

Funder

Shizuoka Industrial Foundation Pharma Valley Center

Taiho Pharmaceutical Co., Ltd.

Novartis Co., Ltd.

Ono Pharmaceutical Co., Ltd.

Yakult Honsha Co., Ltd.

Pfizer Co., Ltd.

Kyowa-Hakko Kirin Co., Ltd.

Teijin Phama Co., Ltd.

Chugai Pharmaceutical Co., Ltd.

AstraZeneca

Boston Scientific

Nippon Kayaku

Kyowa Hakko Kirin

Daiichi Sankyo Co., Ltd.

Ono Pharmaceutical Co., Ltd

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology,Endocrinology, Diabetes and Metabolism

Reference24 articles.

1. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer;Conroy;N Engl J Med,2011

2. Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer;Stein;Br J Canc,2016

3. FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort;Marthey;Ann Surg Oncol,2015

4. FOLFIRINOX induction therapy for stage 3 pancreatic adenocarcinoma;Sadot;Ann Surg Oncol,2015

5. Survival in locally advanced pancreatic cancer after neoadjuvant therapy and surgical resection;Gemenetzis;Ann Surg,2018

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Serum CEA as a Prognostic Marker for Overall Survival in Patients with Localized Pancreatic Adenocarcinoma and Non-Elevated CA19-9 Levels Treated with FOLFIRINOX as Initial Treatment: A TAPS Consortium Study;Annals of Surgical Oncology;2024-01-03

2. Nationwide Use and Outcome of Surgery for Locally Advanced Pancreatic Cancer Following Induction Chemotherapy;Annals of Surgical Oncology;2023-12-17

3. Preoperative chemotherapy, radiotherapy and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer;Nature Reviews Gastroenterology & Hepatology;2023-11-30

4. Clinical impact of multimodal treatment including chemoradiotherapy, conversion surgery and postoperative chemotherapy for borderline resectable and unresectable locally advanced pancreatic cancer without disease progression after gemcitabine plus nab-paclitaxel;Pancreatology;2023-09

5. Clinical Impact of Nutrition and Inflammation Assessment Tools in Pancreatic Cancer Treatment;Anticancer Research;2023-08-30

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3